Change in HbA_1c Across the Baseline HbA_1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.

Gentilella R, Romera I, Nicolay C, Buzzetti R, Vázquez LA, Sesti G

Diabetes therapy : research, treatment and education of diabetes and related disorders4 May 2019Cited by 11 (Europe PMC)

PMID31055780PMCIDPMC6531505DOI10.1007/s13300-019-0625-3PepBankPUB-31055780

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2DM patients, dulaglutide produced similar HbA1c reductions to liraglutide across baseline HbA1c values.
In plain wordsIn T2DM patients, dulaglutide and liraglutide produced similar HbA1c reductions across starting HbA1c values.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHbA1c reduction versus liraglutide
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg once daily
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the continuum of baseline HbA_1c values, patients treated with dulaglutide 1.5 mg achieved a similar mean HbA_1c reduction to patients receiving liraglutide 1.8 mg and a greater reduction than patients receiving twice-daily exenatide or sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
Report a problemFND-3105578005
02HumanRandomized controlled trialEfficacy outcome
In T2DM patients, liraglutide produced similar HbA1c reductions to dulaglutide across baseline HbA1c values.
In plain wordsIn T2DM patients, liraglutide and dulaglutide produced similar HbA1c reductions across starting HbA1c values.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction versus dulaglutide
Study
n: not reported in source
Comparator
Dulaglutide 1.5 mg once weekly
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the continuum of baseline HbA_1c values, patients treated with dulaglutide 1.5 mg achieved a similar mean HbA_1c reduction to patients receiving liraglutide 1.8 mg and a greater reduction than patients receiving twice-daily exenatide or sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
Report a problemFND-3105578006
03HumanRandomized controlled trialEfficacy outcome
In T2DM patients, dulaglutide reduced HbA1c more than twice-daily exenatide across baseline HbA1c values.
In plain wordsIn T2DM patients, dulaglutide reduced HbA1c more than twice-daily exenatide across starting HbA1c values.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction versus exenatide
Study
n: not reported in source
Comparator
Exenatide twice daily
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the continuum of baseline HbA_1c values, patients treated with dulaglutide 1.5 mg achieved a similar mean HbA_1c reduction to patients receiving liraglutide 1.8 mg and a greater reduction than patients receiving twice-daily exenatide or sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
Report a problemFND-3105578007
04HumanRandomized controlled trialEfficacy outcome
In T2DM patients, dulaglutide reduced HbA1c more than sitagliptin across baseline HbA1c values.
In plain wordsIn T2DM patients, dulaglutide reduced HbA1c more than sitagliptin across starting HbA1c values.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction versus sitagliptin
Study
n: not reported in source
Comparator
Sitagliptin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the continuum of baseline HbA_1c values, patients treated with dulaglutide 1.5 mg achieved a similar mean HbA_1c reduction to patients receiving liraglutide 1.8 mg and a greater reduction than patients receiving twice-daily exenatide or sitagliptin.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
Report a problemFND-3105578008
05HumanRandomized controlled trialEfficacy outcome
In AWARD-5 patients, dulaglutide's HbA1c reduction advantage over sitagliptin increased with baseline HbA1c.
In plain wordsIn AWARD-5 patients, dulaglutide reduced HbA1c progressively more than sitagliptin as starting HbA1c increased.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTreatment-by-baseline HbA1c interaction
Study
n: not reported in source
Comparator
Sitagliptin
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
In AWARD-5, the treatment-by-baseline HbA_1c interaction P value (0.001) demonstrated progressively greater HbA_1c reduction in dulaglutide-treated compared with sitagliptin-treated patients as baseline HbA_1c increased.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
Report a problemFND-3105578009

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2DM patients, HbA1c improved across the baseline range in all treatment groups, including dulaglutide.
In plain wordsIn T2DM patients, HbA1c improved across the baseline range in all groups, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c across baseline range
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Improvements in HbA_1c occurred in all treatment groups across the entire baseline HbA_1c range.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3105578001
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In T2DM patients, HbA1c improved across the baseline range in all treatment groups, including liraglutide.
In plain wordsIn T2DM patients, HbA1c improved across the baseline range in all groups, including liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c across baseline range
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Improvements in HbA_1c occurred in all treatment groups across the entire baseline HbA_1c range.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3105578002
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In T2DM patients, higher baseline HbA1c predicted linearly greater reductions in all treatment groups, including liraglutide.
In plain wordsIn T2DM patients, higher starting HbA1c was linked to greater reductions in all groups, including liraglutide.
Peptide
Liraglutide
Outcome
Not applicableBaseline HbA1c and treatment response
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The relationship between HbA_1c baseline and magnitude of change was linear in all treatment groups, with greater reductions in patients with higher baseline HbA_1c values.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3105578004
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In T2DM patients, higher baseline HbA1c predicted linearly greater reductions in all treatment groups, including dulaglutide.
In plain wordsIn T2DM patients, higher starting HbA1c was linked to greater reductions in all groups, including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBaseline HbA1c and treatment response
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The relationship between HbA_1c baseline and magnitude of change was linear in all treatment groups, with greater reductions in patients with higher baseline HbA_1c values.
2 context sentences(design, population, supporting numbers)
Summary · context
This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA_1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA_1c values using data from three phas…
Summary · context
Data from patients receiving once-weekly dulaglutide 0.75 and 1.5 mg, once-daily sitagliptin 100 mg, once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg in the intent-to-treat populations in the AWARD-5, AWARD-6 and AWARD-1 trials
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3105578003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Change in HbA_1c Across the Baseline HbA_1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.

Summary

Results from this study9

Studies that did not test the peptide alone4

Version history

Subjects

Publication types

Keywords